文献速递艾滋病与性传播感染

在病毒学抑制的HIV感染者中达芦那韦/利托那韦减量方案(800/100降至400/100 mg每日一次)的药代动力学建模:ANRS 165 DARULIGHT子研究

Pharmacokinetic modelling of darunavir/ritonavir dose reduction (800/100 to 400/100 mg once daily) in a darunavir/ritonavir-containing regimen in virologically suppressed HIV-infected patients: ANRS 165 DARULIGHT sub-study.
PubMed 文献 · J Antimicrob Chemother · 2018-01-01

ANRS 165 DARULIGHT子研究对15例病毒学抑制的HIV感染者将达芦那韦/利托那韦从800/100 mg每日一次减至400/100 mg每日一次,比较减量前后血浆总/游离达芦那韦及利托那韦药代动力学和精液穿透。结果显示达芦那韦日剂量减半后血浆总及游离暴露无显著下降(AUC0-24 65 563 vs 52 518 ng·h/mL,P=0.25),第12周达芦那韦和利托那韦表观口服清除率下降。

要点

  • 达芦那韦日剂量从800 mg减至400 mg后血浆总及游离暴露无显著下降(AUC0-24 65 563 vs 52 518 ng·h/mL,P=0.25)。
  • 第12周达芦那韦和利托那韦表观口服清除率(CL/F)均下降,提示初始日剂量平衡(800/100至400/100 mg)发生改变。
  • 作者认为减量后达芦那韦对细胞色素P450和外排转运体的诱导效应较标准剂量减弱。

核心结论

  • 达芦那韦日剂量从800 mg减至400 mg后血浆总及游离达芦那韦暴露无显著下降(AUC0-24 65 563 vs 52 518 ng·h/mL,P=0.25)。
  • 第12周达芦那韦和利托那韦表观口服清除率(CL/F)均下降,提示初始达芦那韦/利托那韦日剂量平衡(800/100至400/100 mg)发生改变,作者认为这与减量后达芦那韦对细胞色素P450和外排转运体的诱导效应较标准剂量减弱有关。

研究设计与样本

  • ANRS 165 DARULIGHT研究(NCT02384967)的子研究,纳入接受含达芦那韦/利托那韦(800/100 mg q24h)方案>6个月且血浆HIV-RNA≤50 copies/mL>12个月的患者,第0周切换为达芦那韦/利托那韦400/100 mg q24h。
  • 在减量前(第0周)和减量后(第12周)分别进行24小时密集药代动力学采血和 trough 精液采样。
  • 采用非线性混合效应模型估算血浆达芦那韦/利托那韦个体药代动力学参数并进行生物等效性检验,精液达芦那韦/利托那韦及NRTIs采用非房室分析法。
  • 15例患者完成密集药代动力学分析。

主要发现

  • 达芦那韦日剂量从800 mg减至400 mg(降低50%)后,血浆总及游离达芦那韦暴露无显著下降(AUC0-24 = 65 563 vs 52 518 ng·h/mL;P = 0.25)。
  • 第12周达芦那韦和利托那韦的表观口服清除率(CL/F)均下降。
  • 作者认为CL/F下降提示初始达芦那韦/利托那韦日剂量平衡(800/100至400/100 mg)发生改变,减量后达芦那韦对细胞色素P450和外排转运体的诱导效应较标准剂量减弱。

关键数值与推荐

  • 达芦那韦/利托那韦减量方案:从800/100 mg q24h减至400/100 mg q24h。
  • 入组条件:接受含达芦那韦/利托那韦(800/100 mg q24h)方案>6个月,且血浆HIV-RNA≤50 copies/mL>12个月。
  • 药代动力学采样时间点:减量前(第0周)和减量后(第12周)。
  • 血浆达芦那韦AUC0-24:减量前65 563 vs 减量后52 518 ng·h/mL(P = 0.25)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: In the ANRS 165 DARULIGHT study (NCT02384967) carried out in HIV-infected patients, the use of a darunavir/ritonavir-containing regimen with a switch to a reduced dose of darunavir maintained virological efficacy (≤50 copies/mL) for 48 weeks with a good safety profile. OBJECTIVES: To assess the total and unbound blood plasma pharmacokinetics of darunavir and associated antiretrovirals, and their penetration into semen before and after dose reduction. PATIENTS AND METHODS: Patients receiving a darunavir/ritonavir (800/100 mg q24h)-containing regimen for >6 months with plasma HIV-RNA ≤50 copies/mL for >12 months were switched to 400/100 mg darunavir/ritonavir q24h at week 0. A 24 h intensive pharmacokinetic blood sampling and a trough seminal sampling were performed before (week 0) and after (week 12) dose reduction. Individual pharmacokinetic parameter estimates were obtained using non-linear mixed-effect modelling for darunavir/ritonavir in blood plasma and used to test for bioequivalence, whereas darunavir/ritonavir in seminal plasma and NRTIs were analysed using a non-compartmental approach. RESULTS AND CONCLUSIONS: Fifteen patients completed the intensive pharmacokinetic analysis. There was no significant decrease in total and unbound darunavir blood plasma exposure despite a 50% decrease in darunavir daily dose from 800 to 400 mg (AUC0-24 = 65 563 versus 52 518 ng·h/mL; P = 0.25). A decrease in apparent oral clearance (CL/F) of both darunavir and ritonavir at week 12 suggests a modification of the initial darunavir/ritonavir daily dose balance (800/100 to 400/100 mg), in favour of a reduced inducer effect of darunavir on cytochrome P450 and efflux transporters compared with the standard dose.

来源:J Antimicrob Chemother,查看原文。版权归原作者所有。

引用

  1. Lê MP, Chaix ML, Chevret S, et al. Pharmacokinetic modelling of darunavir/ritonavir dose reduction (800/100 to 400/100 mg once daily) in a darunavir/ritonavir-containing regimen in virologically suppressed HIV-infected patients: ANRS 165 DARULIGHT sub-study. J Antimicrob Chemother. 2018. PMID: 29905808. doi:10.1093/jac/dky193

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。